Unpaired Generative Molecule-to-Molecule Translation for Lead Optimization

Guy Barshatski, Kira Radinsky
{"title":"Unpaired Generative Molecule-to-Molecule Translation for Lead Optimization","authors":"Guy Barshatski, Kira Radinsky","doi":"10.1145/3447548.3467120","DOIUrl":null,"url":null,"abstract":"Molecular lead optimization is an important task of drug discovery focusing on generating novel molecules similar to a drug candidate but with enhanced properties. Prior works focused on supervised models requiring datasets of pairs of a molecule and an enhanced molecule. These approaches require large amounts of data and are limited by the bias of the specific examples of enhanced molecules. In this work, we present an unsupervised generative approach with a molecule-embedding component that maps a discrete representation of a molecule to a continuous space. The components are then coupled with a unique training architecture leveraging molecule fingerprints and applying double cycle constraints to enable both chemical resemblance to the original molecular lead while generating novel molecules with enhanced properties. We evaluate our method on multiple common molecular optimization tasks, including dopamine receptor (DRD2) and drug likeness (QED), and show our method outperforms previous state-of-the-art baselines. Moreover, we conduct thorough ablation experiments to show the effect and necessity of important components in our model. Furthermore, we demonstrate our method's ability to generate FDA-approved drugs it has never encountered before, such as Perazine and Clozapine, which are used to treat psychotic disorders, like Schizophrenia. The system is currently being deployed for use in the Targeted Drug Delivery and Personalized Medicine laboratories generating treatments using nanoparticle-based technology.","PeriodicalId":421090,"journal":{"name":"Proceedings of the 27th ACM SIGKDD Conference on Knowledge Discovery & Data Mining","volume":"116 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the 27th ACM SIGKDD Conference on Knowledge Discovery & Data Mining","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1145/3447548.3467120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Molecular lead optimization is an important task of drug discovery focusing on generating novel molecules similar to a drug candidate but with enhanced properties. Prior works focused on supervised models requiring datasets of pairs of a molecule and an enhanced molecule. These approaches require large amounts of data and are limited by the bias of the specific examples of enhanced molecules. In this work, we present an unsupervised generative approach with a molecule-embedding component that maps a discrete representation of a molecule to a continuous space. The components are then coupled with a unique training architecture leveraging molecule fingerprints and applying double cycle constraints to enable both chemical resemblance to the original molecular lead while generating novel molecules with enhanced properties. We evaluate our method on multiple common molecular optimization tasks, including dopamine receptor (DRD2) and drug likeness (QED), and show our method outperforms previous state-of-the-art baselines. Moreover, we conduct thorough ablation experiments to show the effect and necessity of important components in our model. Furthermore, we demonstrate our method's ability to generate FDA-approved drugs it has never encountered before, such as Perazine and Clozapine, which are used to treat psychotic disorders, like Schizophrenia. The system is currently being deployed for use in the Targeted Drug Delivery and Personalized Medicine laboratories generating treatments using nanoparticle-based technology.
导联优化的未配对生成分子到分子转化
分子先导优化是一项重要的药物发现任务,其重点是生成与候选药物相似但具有增强性质的新分子。先前的工作集中在需要分子对和增强分子对数据集的监督模型上。这些方法需要大量的数据,并且受到增强分子的特定例子的偏见的限制。在这项工作中,我们提出了一种带有分子嵌入组件的无监督生成方法,该方法将分子的离散表示映射到连续空间。然后将组件与利用分子指纹和应用双循环约束的独特训练架构相结合,以使化学相似于原始分子铅,同时生成具有增强性能的新分子。我们在多个常见的分子优化任务中评估了我们的方法,包括多巴胺受体(DRD2)和药物相似性(QED),并表明我们的方法优于先前的最先进的基线。此外,我们进行了彻底的烧蚀实验,以证明我们的模型中重要组件的作用和必要性。此外,我们证明了我们的方法能够产生fda批准的以前从未遇到过的药物,如Perazine和氯氮平,用于治疗精神分裂症等精神疾病。该系统目前正用于靶向药物输送和个性化医学实验室,使用基于纳米颗粒的技术产生治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信